uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
Mizuho on uniQure BV (QURE): 'expressed confidence the overall signal — namely the slowing of disease progression — should remain directionally consistent'
June 17, 2026 1:27 PM EDTMizuho analyst Uy Ear reiterated an Outperform rating and $35.00 price target on uniQure BV (NASDAQ: QURE).
The analyst comments "FDA Under New Leadership Seems to Signal Renewed Flexibility in Rare Diseases: Regarding the Type B meeting, management noted the core review team remained largely unchanged, but leadership-level discussions seem to have enabled a more pragmatic path forward, which led to the agency's willingness to find the 3-year Phase I/II results as supportive of an Accelerated BLA filing and non-sham control confirmatory Phase 3 trial. Management highlighted a constructive shift in tone following recent... More
uniQure BV (QURE) PT Raised to $71 at Stifel
June 17, 2026 9:31 AM EDTStifel analyst Paul Matteis raised the price target on uniQure BV (NASDAQ: QURE) to $71.00 (from $28.00) while maintaining a Buy rating.
The analyst comments "We're reiterating our Buy rating on QURE and raising our TP to $71, on the back of a positive and welcome surprise around FDA's ~180 on the regulatory path for AMT-130 (LINK). Bottom line: we now model a slightly greater than 50%... More
